IBM names chief health officer for Watson Health Unit

Beth Walsh | | Health Exec | Precision Medicine

IBM has appointed Kyu Rhee, MD, chief health officer for the Watson Health Unit, according to Fortune.

Rhee currently serves as chief health officer of IBM, and will continue serving this position in addition to his new role. As chief health officer of the Watson Health Unit, Rhee will oversee building a community of health professionals, making sure provider needs are met and working toward new growth areas for the health data platform, according to Fortune. He is expected to "drive the business forward with a focus on clinical and population health expertise."

Prior to IBM, Rhee was chief public health officer at the Health Resources and Services Administration, and director of the Office of Innovation and Program Coordination at the National Institutes of Health.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup